PerkinElmer to acquire RHS
Adelaide-based single cell genomics company, RHS Limited, has entered into an agreement for PerkinElmer to acquire all issued share capital in RHS for 28 cents per share.
The deal, unanimously recommended by the board of RHS, will see a 100% premium paid for shares on the last listed share price for RHS, recorded on 23 February 2018.
RHS shareholders will vote on the deal at a meeting in May 2018.
RHS CEO Dr Michelle Fraser stated “The offer from PerkinElmer reinforces the considerable expertise that the RHS team have integrated into each of our products. Bringing RHS and PerkinElmer together provides an opportunity for our products to reach the clinical and applied research markets through a large and highly experienced global team.”
Read the ASX release here.